Antiestrogen therapy for Hereditary hemorrhagic telangiectasia: A double-blind placebo-controlled clinical trial

Laryngoscope

Volumn 119, Issue 2, 2009, Pages 284-288

  Yaniv, Eitan ^a,b   Preis, Michal ^a,b   Hadar, Tuvia ^a,b   Shvero, Jacob ^a,b   Haddad, Miriam ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Epistaxis; Hereditary hemorrhagic telangiectasia; Tamoxifen

Indexed keywords

ANTIESTROGEN; PLACEBO; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPISTAXIS; FEMALE; GENDER; HEMOGLOBIN DETERMINATION; HUMAN; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; HOSPITALIZATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; DOUBLE-BLIND METHOD; EPISTAXIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; TAMOXIFEN; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME;

EID: 63249096929     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20065     Document Type: Article

References (28)

1. Hanes FM. Multiple hereditary telangiectasia causing hemorrhage (hereditary hemorrhagic telangiectasia). Bull Johns Hopkins Hosp 1909; 20:63-75.
2. Gibbs DD. Rendu-Osler-Weber disease: a triple eponymous title lives on. J R Soc Med 1986; 79:742-743.
3. Haitjema T., Westermann CJ, Overtoom TT, et al. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications and treatment. Arch Intern Med 1996; 156:714-719.
4. Assar OS, Friedman CM, White RI Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101:977-980.
5. Shah RK, Dhingra JK, Shapshay SM. Hereditary hemorrhagic telangiectasia: a review of 76 cases. Laryngoscope 2002; 112:767-773.
6. Pau H., Carney AS, Murty GE. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations. Clin Otolaryngol 2001; 26: 93-98.
7. Larson AM. Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2003; 36:149-158.
8. Reilly PJ, Nostrant TT. Clinical manifestations of hereditary hemorrhagic telangiectasia. Am J Gastroenterol 1984; 79:363-367.
9. Shapsay SM, Oliver P. Treatment of hereditary hemorrhagic telangiectasia by Nd-YAG laser photocoagulation. Laryngoscope 1984; 94:1554-1556.
10. Pohar S., Mazeron JJ, Ghilezan M., et al. Management of epistaxis in Rendu-Osler disease: is brachytherapy effective? Int J Radiat Bio Phys 1993; 27:1073-1077.
11. Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 330:1789-1790.
12. Klepfish A., Berrebi A., Schattner A., et al. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161: 767.
13. Koch HJ, Escher GC, Lewis JS. Hormonal management of hereditary hemorrhagic telangiectasia. JAMA 1952; 149: 1376-1380.
14. Harrison DFN. Familial haemorrhagic telangiectasia: 20 cases treated with systemic oestrogen. Q J Med 1964; 33: 25-38.
15. Harrison DFN. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope 1982; 92: 314-320.
16. Flessa HC, Glueck HI. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol 1977; 103:148-151.
17. Van Cutsem E., Rutgeerts P., Geboes K., et al. Estrogen-progesterone treatment of Osler-Weber-Rendu disease. J Clin Gastroenterol 1988; 10:676-679.
18. Richtsmeier W., Weaver G., Streck W., et al. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1984; 92:564-570.
19. Tombleson PMJ. Local oestrogen for recurrent epistaxis caused by familial telangiectasia. J Roy Coll Gen Pract 1988; May:227.
20. Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. Acta Med Scand 1981; 209:393-396.
21. Sabba C., Pasculli G., Cirulli A., et al. Rendu-Osler-Weber disease: experience with 56 patients. Ann Ital Med Int 2002; 17:173-179.
22. Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2004; 114:750-759.
23. Pau H., Carney AS, Walker R., Murty GE. Is estrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia: a biochemical evaluation. Clin Otolaryngol 2000; 25:547-550.
24. Bergler W., Sadick H., Gotte K., et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinl Laryngol 2002; 111:222-228.
25. Shovlin CL, Gottmachen AF, Buscanini E., et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Ann J Med Gen 2000; 91: 66-67.
26. Fernandez-L A., Sanz-Rodriguez F., Blanco FJ, et al. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-β signaling pathway. Clin Med Res 2006; 4:66-78.
27. Sadick H., Sadick M., Gotte K., et al. Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures. Wien Klin Wochenschr 2006; 118: 72-80.
28. Bossler AD, Richards J., George C., Godmilow L., Ganguly A. Novel mutations in ENG and ACVRLI identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia: correlation of genotype with phenotype. Hum Mutat 2006; 27: 667-675.